ipscell.com
Great News: FDA Nod For ViaCyte IND of Diabetes Stem Cell-Based Product - The Niche
ViaCyte just got FDA approval for its investigational new drug (IND), paving the way to start a combined Phase I/II clinical trial for Diabetes.
Professor Paul Knoepfler, Ph.D.